Rigel Pharmaceuticals GAAP EPS of $13.54 beats by $12.31, revenue of $69.8M beats by $1.1M

* Rigel Pharmaceuticals press release [https://seekingalpha.com/pr/20422791-rigel-provides-fourth-quarter-and-full-year-2025-financial-results-and-provides-business] (RIGL [https://seekingalpha.com/symbol/RIGL]): Q4 GAAP EPS of $13.54 beats by $12.31.
* Revenue of $69.8M (+21.2% Y/Y) beats by $1.1M.
*
Rigel anticipates 2026 total revenues of approximately $275 to $290 million, including:

* Net product sales of approximately $255 to $265 million.
* Contract revenues of approximately $20 to $25 million.

MORE ON RIGEL PHARMACEUTICALS

* Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 [https://seekingalpha.com/article/4862768-rigel-pharmaceuticals-stock-continued-financial-performance-catalysts-2026]
* Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript [https://seekingalpha.com/article/4860031-rigel-pharmaceuticals-inc-rigl-presents-at-44th-annual-j-p-morgan-healthcare-conference]
* Rigel Pharma: Formulating A Game Plan For 2026 [https://seekingalpha.com/article/4856671-rigel-pharmaceuticals-stock-formulating-game-plan-2026]
* Rigel Pharmaceuticals Q4 2025 Earnings Preview [https://seekingalpha.com/news/4559894-rigel-pharmaceuticals-q4-2025-earnings-preview]
* Top Quant rated bullish small cap stocks among companies with high short interest [https://seekingalpha.com/news/4549737-top-quant-rated-bullish-small-cap-stocks-among-companies-with-high-short-interest]